Lipidomic Profiling of Plasma Samples in Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study for Predicting the Response and Toxicities of Melphalan, Prednisolone and Bortezomib (MPB) Regimen : An Ancillary Study of the JCOG1105 (JCOG1105A1)

Background Although the proteasome inhibitor bortezomib (Btz) shows excellent efficacy in multiple myeloma (MM), some patients exhibit sub-optimal or no response to this agent. In addition, Btz-induced toxicity, such as peripheral neuropathy (PN) and skin disorders, limits its use in some patients. A comprehensive analysis of metabolites (metabolomics) in biofluids can be a potential novel strategy to predict the efficacy or adverse events of...